<DOC>
	<DOCNO>NCT00426868</DOCNO>
	<brief_summary>The purpose study establish safety feasibility utilize Adipose Derived Stem &amp; Regenerative Cells ( ADRCs ) patient area myocardium revascularizable demonstrate reversible ischemia .</brief_summary>
	<brief_title>A Randomized Clinical Trial Adipose-derived Stem Cells Treatment Non Revascularizable Ischemic Myocardium</brief_title>
	<detailed_description>Subjects coronary artery disease revascularized demonstrate reversible ischemia area supply non-revascularizable vessel ( ) evaluate eligibility study . Eligible subject undergo standard pre-operative test admission hospital , undergo liposuction anesthesia , ADRCs isolate lipoaspirate . According randomization subject receive either ADRCs placebo . The outcome trial base assessment primary secondary endpoint 6 month post index procedure . Long Term Follow-up conduct 12 , 18 , 24 36 month procedure .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<criteria>Key Able provide write informed consent Males females 20 75 year age , inclusive Coronary artery disease amenable type revascularization procedure ( percutaneous surgical ) target area Hemodynamic stability Ability undergo liposuction Ability walk treadmill Negative urine pregnancy test ( female ) . Key Unstable angina Serum creatinine &gt; 2.5 mg/dL Planned schedule stag treatment CAD interventional surgical procedure Cardiogenic shock History resuscitate sudden cardiac death ; symptomatic sustain ventricular fibrillation ventricular tachycardia . Vascular anatomy precludes cardiac catheterization Peripheral artery disease preclude insertion 8 Fr sheath Severe valvular disease Pregnant nursing female Known relevant allergy sensitivities Life expectancy &lt; 1 year Participation clinical research study reach primary endpoint otherwise would interfere subject 's participation study Any concurrent disease condition , opinion investigator , would make subject unsuitable participation study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>ADRC</keyword>
	<keyword>Stem Cells</keyword>
	<keyword>chronic ischemia</keyword>
	<keyword>heart disease</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>inducible reversible ischemia</keyword>
</DOC>